peptide
Adipotide (FTPP)
anecdotalResearch Use OnlyInjection
DISCONTINUED. Experimental peptide that cuts blood supply to fat cells. Terminated due to unacceptable kidney toxicity in primates. No human trials conducted.
Key facts
- Classification
- Peptide — DISCONTINUED: Experimental peptide that cuts blood supply to fat cells. Terminated due to kidney toxicity.
- Primary benefits
- Fat Loss (4/10)
- Administration
- Injection
- Doses studied
- Research protocols suggest approximately 0.01 mg/kg subq daily. Primate studies at higher doses (0.25-0.75 mg/kg) caused renal tubular injury. Keep cycles extremely short (2 weeks max) and monitor kidney function closely. Development was terminated for safety reasons -- use at your own risk.
- Evidence strength
- Anecdotal — 8 peer-reviewed studies
- Legal status
- Research Use Only · not prescribable in US
Quick stats
- Type
- Peptide
- Administration
- Injection
- Studies referenced
- 8
- Stacks with
- 0 peptides
- Regulatory
- Research Use Only
Goal coverage · Adipotide (FTPP)
🔥 Fat Loss4/10
Medical oversight requiredNot safe during pregnancy· 5 contraindications